{"nctId":"NCT03151967","briefTitle":"Lactobacillus Probiotic for Prevention of UTI","startDateStruct":{"date":"2015-09","type":"ACTUAL"},"conditions":["Urinary Tract Infections (UTI's)"],"count":27,"armGroups":[{"label":"Applicator with LACTIN-V Treatment","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lactobacillus crispatus CTV-05"]},{"label":"Applicator with Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Lactobacillus crispatus CTV-05","otherNames":["Lactin-V"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* pre-menopausal women\n* present with an acute, uncomplicated, culture confirmed UTI, defined as dysuria, urgency and/or frequency\n* at least one previous medically diagnosed UTI in past 12 months\n* using a reliable method of birth control ie: history of tubal ligation, male partner with vasectomy, steroidal contraception, Nuva-Ring, IUD, use of non spermicidal condoms or abstinence.\n* can provide written consent\n* can understand and read English\n\nExclusion Criteria:\n\n* history of urogenital infection within the past 30 days, including: UTI, medically diagnosed vaginitis\n* current symptoms suggestive of pyelonephritis (fever\\>100.4, flank pain of costovertebral angle tenderness, nausea and vomiting\n* history of functional or anatomic urologic abnormalities, urologic surgery of chronic urinary catheterization\n* history of pyelonephritis within the past 6 months\n* diagnosis of N. gonorrhoeae, C. trachomatis or T. vaginalis on two or more occasions during previous six months\n* known HIV infection of seropositivity\n* investigational drug use within 30 days of enrollment visit or current participation in another clinical trial\n* diabetes, other significant medical problem or intercurrent acute illness that in the Nurse Practitioner's and/or Principal Investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objective.\n\nAt the randomization visit, has any of the following findings on pelvic or other physical examination:\n\n* unable to visualize cervix\n* clinically significant abnormalities, such as inflammation, erosion and/or petechiae (bleeding under the skin) of external genitalia, vaginal or cervix on visual examination\n* clinically significant tenderness on bimanual examination during the pelvic examination\n* evidence of vaginitis or a sexually-transmitted disease\n* any diagnosis requiring antibiotics","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"UTI Incidence as Described Below, Over the 16 Week Study Period Following Randomization, in the LACTIN-V Treatment Group (Group A) as Compared to the Placebo Group (Group B).","description":"Symptomatic UTI : Comparison of the number (%) of subjects over the 16-week study period following randomization, with at least one symptomatic UTI (as defined above) in the 2 intervention groups","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Parameter of Vaginal Colonization","description":"Lactobacillus crispatus positive (as assessed by repPCR) at Weeks 0,2,6,10,14, and 18 in the Lactin-V group as compared to the placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":14},"commonTop":["Reproductive system and breast disorders","Infections and Infestations","Renal and urinary disorders","Gastrointestinal disorders","Nervous system disorders"]}}}